Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease

Blood

Volumn 119, Issue 10, 2012, Pages 2228-2233

  Gérard, Laurence ^a   Michot, Jean Marie ^a   Burcheri, Sara ^a   Fieschi, Claire ^a   Longuet, Pacale ^b   Delcey, Véronique ^c   Meignin, Véronique ^a   Agbalika, Felix ^a   Chevret, Sylvie ^a   Oksenhendler, Eric ^a   Galicier, Lionel ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; RITUXIMAB;

ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION;

EID: 84858067317     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-376012     Document Type: Article

References (28)

1. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10(1):61-67. (Pubitemid 26016404)
2. Du M-Q, Bacon CM, Isaacson PG. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol. 2007;60(12):1350-1357. (Pubitemid 350247250)
3. Dupin N, Gorin I, Deleuze J, et al. Herpes-like DNA sequences, AIDS-related tumors, and Castleman's disease. N Engl J Med. 1995; 333(12):798-799.
4. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995;86(4):1276-1280.
5. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and c reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood. 2000;96(6):2069-2073.
6. Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-associated multicentric Castleman's disease. J Clin Oncol. 2011; 29(18):2481-2486.
7. Dupin N, Fisher C, Kellam P, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A. 1999;96(8):4546-4551. (Pubitemid 29190373)
8. Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood. 2001;97(7):2130-2136. (Pubitemid 32239096)
9. Dargent J-L, Lespagnard L, Sirtaine N, et al. Plasmablastic microlymphoma occurring in human herpesvirus 8 (HHV-8)-positive multicentric Castleman's disease and featuring a follicular growth pattern. APMIS. 2007;115(7):869-874. (Pubitemid 47030104)
10. Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002;99(7):2331- 2336.
11. Fakhari FD, Jeong JH, Kanan Y, Dittmer DP. The latency-associated nuclear antigen of Kaposi sarcoma- associated herpesvirus induces B cell hyperplasia and lymphoma. J Clin Invest. 2006; 116(3):735-742. (Pubitemid 43326882)
12. Hoffmann C, Schmid H, Müller M, et al. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood. 2011;118(13):3499-3503.
13. Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for kaposi sarcoma herpesvirus-associated multicentric castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood. 2011;117(26):6977- 6986.
14. Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007; 147(12):836-839. (Pubitemid 351664423)
15. Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB trial. J Clin Oncol. 2007;25(22):3350- 3356.
16. Ascoli V, Signoretti S, Onetti-Muda A, et al. Primary effusion lymphoma in hiv-infected patients with multicentric castleman's disease. J Pathol. 2001;193(2):200-209. (Pubitemid 32118132)
17. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95(4):1406-1412. (Pubitemid 30099854)
18. Swerdlow S, Campo E, Harris NL, eds; International Agency for Research on Cancer. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Geneva: World Health Organization; 2008.
19. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
20. Rubin D. Multiple Imputation for Non-Response in Surveys. New York, NY: John Wiley; 1987.
21. Leuven E, Sianesi B. PSMATCH2: Stata module to perform full mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. Available at: http://ideas- .repec.org/c/boc/bocode/s432001.html. Accessed November 10, 2010.
22. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48(5): 590-598.
23. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20(12): 1645-1654. (Pubitemid 44162407)
24. Bonnet F, Balestre E, Thiébaut R, et al. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine cohort, France. Clin Infect Dis. 2006;42(3):411-417. (Pubitemid 43122322)
25. Bohlius J, Schmidlin K, Costagliola D, et al. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a european multicohort study. Antivir Ther. 2009;14(8):1065-1074.
26. Stebbing J, Gazzard B, Newsom-Davis T, et al. Nadir b cell counts are significantly correlated with the risk of kaposi's sarcoma. Int J Cancer. 2004;108(3):473-474. (Pubitemid 37549615)
27. Stratigos AJ, Malanos D, Touloumi G, et al. Association of clinical progression in classic kaposi's sarcoma with reduction of peripheral b lymphocytes and partial increase in serum immune activation markers. Arch Dermatol. 2005;141(11): 1421-1426. (Pubitemid 41668695)
28. Pantanowitz L, Früh K, Marconi S, Moses AV, Dezube BJ. Pathology of rituximab-induced kaposi sarcoma flare. BMC Clin Pathol. 2008;8:7.